| Document Date: 2014-10-10 07:50:13
Open Document File Size: 37,13 KBShare Result on Facebook
City Tarrytown / New York / Paris / / Company AEs / Genzyme / Bayer HealthCare LLC / Regeneron Pharmaceuticals Inc. / Sanofi / / Continent Europe / / Country United States / / Event Business Partnership / Company Listing Change / FDA Phase / / IndustryTerm healthcare / therapeutic solutions / consumer healthcare / science-based biopharmaceutical / supply chains / therapeutic applications / diabetes solutions / / MedicalCondition allergic disease / allergic inflammatory process / atopic dermatitis / headache / colorectal cancer / another allergic inflammatory condition / mucosal inflammation / rheumatoid arthritis / nasal polyps / moderate-to-severe chronic sinusitis / nasal obstruction / rare inflammatory condition / allergic inflammation / sinusitis / Chronic Sinusitis / asthma / Nasal Polyps CSwNP / epistaxis / nasopharyngitis / diabetes / pain / runny nose / dizziness / sleep dysfunction / eye diseases / hypercholesterolemia / facial pain / / MedicalTreatment surgery / sinus surgery / drainage / investigational therapy / / Organization United States Securities and Exchange Commission / Medicare / National Park Service / / Person Neil Graham / Gianluca Pirozzi / / Position Vice President / Program Management / global healthcare leader / Vice President / Global Project Head / / Product IL-4 / / ProvinceOrState New York / / Technology alpha / therapeutic solutions / SAN / / URL www.regeneron.com / /
SocialTag |
PRESS RELEASE Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps Paris and Tarrytown, N.Y. – September 30, [removed]Sanofi and Regeneron Pharma